DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today that its Board of Directors has approved a four-for-one forward split of Dexcom’s common stock.
The Stock Split is contingent upon stockholder approval of a Restated Certificate of Incorporation that would increase the number of authorized shares of common stock from 200,000,000 to 800,000,000.
If stockholders approve the Stock Split, each share of common stock outstanding on May 19, the date of Dexcom’s 2022 Annual Meeting of Stockholders, will be split into four shares of common stock. Trading is expected to begin on a split-adjusted basis on June 10.
Dexcom empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe, Dexcom has emerged as a leader of diabetes care technology.
According to the Motley Fool, the company has some of the trappings that can make for a winner. Its returns have crushed the market over the last five years, with its shares rising by more than 487% against the market’s rise of nearly 106%. Could it repeat this feat in the future? The “Fool” authors say “it’s possible, but that doesn’t necessarily make it the right stock for everyone.”
DXCM opened Friday up $10.96, or 2.3%, to $479.35